Overview

Applied Molecular Evolution Inc. applies its directed molecular evolution technology platform, AMEsystem, to improve health care by optimizing and developing human biotherapeutics. AME optimizes the full range of proteins, including antibodies, cytokines, hormones and enzymes, to develop improved versions of currently marketed, FDA-approved biotherapeutics, as well as novel human biopharmaceuticals.

The AMEsystem selectively replaces single amino acids in target proteins, evaluates the resulting protein for improvements and combines positive changes until an optimized protein is produced. DirectAME is a patented gene synthesis process that enables the company to rapidly produce a library of diverse genes altered from an initial gene. ExpressAME consists of several gene expression systems that produce proteins from the genes generated using DirectAME. SelectAME is a series of tests or screens that facilitate the selection and identification of proteins with the optimal, desired commercial properties from the protein libraries generated using ExpressAME.

Partners

AME has collaborations with developers of biotherapeutics, including Eli Lilly and Co., Chiron Corp., MedImmune Inc., Bristol-Myers Squibb Co., Seattle Genetics Inc., Cell-Matrix Inc. and Biosynexus Inc.